ALX Oncology Holdings announced the initiation of a Phase 2 investigator-sponsored trial of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA in patients with previously untreated and early-stage locally advanced, resectable, human papillomavirus-mediated oropharyngeal cancer. This multi-center, single-arm, open-label Phase 2 IST is being led by Joseph A. Califano III, M.D., Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center at the University of California, San Diego.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- Cantor Fitzgerald biotech analyst holds an analyst/industry webinar
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
- ALX Oncology reports clinical data from Phase 1/2 trial of evorpacept
- ALX Oncology price target raised to $20 from $17.50 at H.C. Wainwright